Expert opinion on drug discovery · 2025
E protein inhibitors and host-directed therapies in dengue virus infection: perspectives on combination and complementary antiviral strategies.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jiménez-Camacho Ricardo, Farfan-Morales Carlos Noe, De Jesús Bravo-Silva José, Benítez-Vega Magda Lizbeth, Pérez-García Marcos, Hernández-Castillo Jonathan, Cordero-Rivera Carlos Daniel, Del Ángel Rosa María
Аннотация
INTRODUCTION: Dengue virus (DENV) remains a significant global health threat, causing millions of infections and substantial morbidity each year. The viral E protein is a key target for neutralizing antibodies and vaccine design; however, antibody-dependent enhancement (ADE) complicates safe immunization. Currently licensed vaccines offer only partial and serotype-dependent protection, highlighting the urgent necessity for additional therapeutic strategies.
AREAS COVERED: This review summarizes advances in direct-acting antivirals (DAAs) targeting the E protein and host-directed therapies (HDTs). It discusses DAAs that block E-mediated viral entry and HDTs that modulate lipid metabolism, nucleotide biosynthesis, protein folding, translation, and immune pathways. Promising preclinical candidates and experimental DAAs-HDTs combinations with synergistic activity are highlighted, alongside persistent challenges related to viral diversity, ADE risk, host toxicity, and translational limitations. Relevant literature was identified through PubMed, Scopus, Web of Science, ClinicalTrials.gov, and WHO databases, including recent and foundational studies up to September 2025.
EXPERT OPINION: Combining DAAs with HDTs represents a rational strtategy to enhance antiviral efficacy, broaden serotype coverage, reduce resistence, and pontentially limit toxicity. Although clinical evidence remains limited, expandend preclinical and clinical evaluation of these approaches, incorporating serotype-specific testing and sex-based analyses will be essential for advancing effective dengue therapeutics.
AREAS COVERED: This review summarizes advances in direct-acting antivirals (DAAs) targeting the E protein and host-directed therapies (HDTs). It discusses DAAs that block E-mediated viral entry and HDTs that modulate lipid metabolism, nucleotide biosynthesis, protein folding, translation, and immune pathways. Promising preclinical candidates and experimental DAAs-HDTs combinations with synergistic activity are highlighted, alongside persistent challenges related to viral diversity, ADE risk, host toxicity, and translational limitations. Relevant literature was identified through PubMed, Scopus, Web of Science, ClinicalTrials.gov, and WHO databases, including recent and foundational studies up to September 2025.
EXPERT OPINION: Combining DAAs with HDTs represents a rational strtategy to enhance antiviral efficacy, broaden serotype coverage, reduce resistence, and pontentially limit toxicity. Although clinical evidence remains limited, expandend preclinical and clinical evaluation of these approaches, incorporating serotype-specific testing and sex-based analyses will be essential for advancing effective dengue therapeutics.